Navigation Links
Staphylococcus aureus vaccine development on track ? safe and,immunogenic in Phase I clinicaltrials

VIENNA, Austria, May 18, 2007 – Intercell AG (VSE, “ICLL”) has been informed by its strategic partner Merck & Co., Inc. on the results of a Phase I study involving in total over 120 adult healthy volunteers comparing safety and immunogenicity of different doses of the Staphylococcus aureus vaccine.

The Staphylococcus aureus vaccine is based on a conserved protein antigen discovered by Intercell’s Antigen Identification Program (AIP®) and was licensed to Merck & Co., Inc. on an exclusive world wide basis in 2003.

The data show that the vaccine is safe and generally well tolerated. Immune responses were observed within several weeks following vaccination and these immune responses persisted throughout the course of the study.

“We are very pleased that the vaccine candidate, for which the antigen was identified by our proprietary AIP® technology, delivered promising clinical data, and look forward to its further clinical development ”, states Gerd Zettlmeissl, CEO of Intercell. “These data underline the high potential of our AIP® technology for the identification of other bacterial vaccine product candidates in?house or in collaboration with leading vaccine companies”.

About Staphylococcus aureus and nosocomial infections
Hospital?acquired infections are one of the major causes of death and serious illness worldwide,
resulting in an annual burden of more than USD 20 billion in the developed world. In the United
States alone, about two million patients become infected annually while receiving health care in
hospitals. The incidence of nosocomial infections is steadily increasing due to medical
interventions and most notably due to the emergence of antibiotic resistant bacteria circulating in
hospitals. Staphylococcus aureus is the most frequent cause of hospital acquired infections. In
addition to bloodstream infections with a mortality rate of up to 35%, infections of bone, heart and
other inner organs are leading to serious health complications, death and economic burden. Today,
approximately 50% of Staphylococcus aureus strains isolated in hospitals worldwide are resistant to
multiple antibiotics, rendering staphylococcal disease management increasingly difficult and
challenging.

About Intercell AG:
Intercell AG is a growing biotechnology company which focuses on the design and Intercell AG is
a growing biotechnology company which focuses on the design and development of novel
vaccines for the prevention and treatment of infectious diseases with substantial unmet medical
need. The Company develops antigens and adjuvants which are derived from its proprietary
technology platforms, and has in?house GMP manufacturing capability. Based on these
technologies, Intercell has strategic partnerships with a number of global pharmaceutical
companies, including Novartis, Merck & Co., Inc., Wyeth, sanofi pasteur, Kirin and the Statens
Serum Institut.

The Company’s leading product, a prophylactic vaccine against Japanese Encephalitis, successfully
concluded pivotal Phase III clinical trials in 2006. The regulatory process towards a Biologics
License Application (BLA) to the U.S. Food and Drug Administration (FDA) has been initiated.
The broad development pipeline includes a Pseudomonas vaccine in Phase II, a therapeutic
vaccine for Hepatitis C in Phase II, partnered vaccines for Tuberculosis and Staphylococcus aureus
which are in Phase I, and five products focused on infectious diseases in preclinical development.
Intercell is listed on the Vienna stock exchange under the symbol “ICLL”.

For more information please visit: www.intercell.com
Contact Interce ll AG:
Intercell AG
Katharina Wieser
Head of Corporate Communications
Campus Vienna Biocenter 2, A?1030 Vienna
P: +43?1?20620?303 Mail to: kwieser@intercell.com

'"/>




Related medicine technology :

1. Controlling the Spread of Healthcare Associated Methicillin Resistant Staphylococcus aureus Requires Active Surveillance
2. Pharmexa A/S (DK) - Long lasting immune response and survival to RAS vaccine
3. Apollo develops needle-free topical vaccine
4. Pro-Pharmaceuticals to Present Abstract at the International Society of Oncodevelopmental Biology and Medicine Conference
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at www.diabetesscholars.org ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
(Date:6/23/2016)... 2016 Revolutionary technology includes multi-speaker ... , industry leaders in advanced audiology and hearing aid ... Opn ™, the world,s first internet connected hearing aid ... devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) ... of ,world firsts,: , TwinLink™ - the ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 2016 , ... To succeed under value-based payments, healthcare providers ... how to move forward, given the need to sustain current operations. PYA has ... an organization’s specific needs. , PYA Principal Martie Ross states, “Healthcare providers want ...
(Date:6/24/2016)... Brooklyn, New York (PRWEB) , ... June 24, 2016 , ... ... medical marijuana patients optimize the ingestion of their medication by matching users with high ... allows users to compare pieces with no commitment. , Inhale was founded by two ...
(Date:6/24/2016)... ... ... Dr. Seema Daulat, a native Texan and University of Texas at Austin ... July 13, 2016. , Dr. Daulat earned her Doctorate of Medicine (MD) at The ... the Agape Clinic serving Dallas’ underprivileged community. , Following medical school, Dr. Daulat completed ...
(Date:6/23/2016)... Los Angeles, CA (PRWEB) , ... June 23, 2016 , ... ... being conducted that may expose a possible link between head and neck cancer in ... individuals participating in the study were evaluated based on whether they had gum disease, ...
(Date:6/23/2016)... ... ... The Mechille Wilson Agency, a Texas-based insurance company that provides coverage to hundreds ... a charity drive to assist a student to be chosen from the local area. ... be presented to the chosen student to help with the growing costs of tuition, ...
Breaking Medicine News(10 mins):